Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis

Overview

Journal Int J Neuropsychopharmacol

Publisher Oxford University Press

Specialty Psychiatry

Date 2015 May 28

PMID 26012350

Citations 51

Authors

Xinyu Zhou

Gabor I Keitner

Bin Qin

Arun V Ravindran

Michael Bauer

Cinzia Del Giovane

Jingping Zhao

Yiyun Liu

Yiru Fang

Yuqing Zhang

Peng Xie

Affiliations

Soon will be listed here.

Abstract

Background: Previous meta-analyses of atypical antipsychotics for depression were limited by few trials with direct comparisons between two treatments. We performed a network meta-analysis, which integrates direct and indirect evidence from randomized controlled trials (RCTs), to investigate the comparative efficacy and tolerability of adjunctive atypical antipsychotics for treatment-resistant depression (TRD).

Methods: Systematic searches resulted in 18 RCTs (total n = 4422) of seven different types and different dosages of atypical antipsychotics and a placebo that were included in the review.

Results: All standard-dose atypical antipsychotics were significantly more efficacious than placebo in the efficacy (standardized mean differences [SMDs] ranged from -0.27 to -0.43). There were no significant differences between these drugs. Low-dose atypical antipsychotics were not significantly more efficacious than the placebo. In terms of tolerability, all standard-dose atypical antipsychotics, apart from risperidone, had significantly more side-effect discontinuations than placebo (odds ratios [ORs] ranged from 2.72 to 6.40). In terms of acceptability, only quetiapine (mean 250-350 mg daily) had significantly more all-cause discontinuation than placebo (OR = 1.89). In terms of quality of life/functioning, standard-dose risperidone and standard-dose aripiprazole were more beneficial than placebo (SMD = -0.38; SMD = -0.26, respectively), and standard-dose risperidone was superior to quetiapine (mean 250-350 mg daily).

Conclusions: All standard-dose atypical antipsychotics for the adjunctive treatment of TRD are efficacious in reducing depressive symptoms. Risperidone and aripiprazole also showed benefits in improving the quality of life of patients. Atypical antipsychotics should be prescribed with caution due to abundant evidence of side effects.

Citing Articles

Emerging Medications for Treatment-Resistant Depression: A Review with Perspective on Mechanisms and Challenges.

Lucido M, Dunlop B Brain Sci. 2025; 15(2).

PMID: 40002494 PMC: 11853532. DOI: 10.3390/brainsci15020161.

A New Augmentation Strategy against Depression Combining SSRIs and the N-terminal Fragment of Galanin (1-15).

Flores-Burgess A, Millon C, Cantero-Garcia N, Pineda-Gomez J, Flores-Gomez M, Diaz-Cabiale Z Curr Neuropharmacol. 2024; 23(3):295-309.

PMID: 39484753 PMC: 11808584. DOI: 10.2174/1570159X23666241003125019.

How pharmacology can aid in the diagnosis of mental disorders.

Seifert R, Schirmer B, Seifert J Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(2):1099-1110.

PMID: 39230588 PMC: 11825625. DOI: 10.1007/s00210-024-03413-z.

Electroconvulsive therapy for adolescents with severe depressive episode and suicidality: retrospective comparison between responders and non-responders.

Ren H, Wang X, Zhang Z, Zhong X, Luo Q, Qiu H Child Adolesc Psychiatry Ment Health. 2024; 18(1):13.

PMID: 38245725 PMC: 10800036. DOI: 10.1186/s13034-023-00701-z.

Trends in antipsychotic use among children and adolescents in Germany: a study using 2011-2020 nationwide outpatient claims data.

Dorks M, Bachmann C, Below M, Hoffmann F, Paschke L, Scholle O Front Psychiatry. 2023; 14:1264047.

PMID: 38148746 PMC: 10749930. DOI: 10.3389/fpsyt.2023.1264047.

References

Berlim M, Turecki G . Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry. 2007; 52(1):46-54. DOI: 10.1177/070674370705200108. View

Trivedi M, Rush A, Wisniewski S, Nierenberg A, Warden D, Ritz L . Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006; 163(1):28-40. DOI: 10.1176/appi.ajp.163.1.28. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 339:b2535. PMC: 2714657. DOI: 10.1136/bmj.b2535. View

Berard R, Fong R, Carpenter D, Thomason C, Wilkinson C . An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder. J Child Adolesc Psychopharmacol. 2006; 16(1-2):59-75. DOI: 10.1089/cap.2006.16.59. View

Keitner G, Garlow S, Ryan C, Ninan P, Solomon D, Nemeroff C . A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res. 2008; 43(3):205-14. PMC: 3685867. DOI: 10.1016/j.jpsychires.2008.05.003. View

Kessler R, Berglund P, Demler O, Jin R, Koretz D, Merikangas K . The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003; 289(23):3095-105. DOI: 10.1001/jama.289.23.3095. View

Salanti G, Ades A, Ioannidis J . Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2010; 64(2):163-71. DOI: 10.1016/j.jclinepi.2010.03.016. View

Endicott J, Nee J, Harrison W, Blumenthal R . Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993; 29(2):321-6. View

Brunoni A, Lopes M, Kaptchuk T, Fregni F . Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysis. PLoS One. 2009; 4(3):e4824. PMC: 2653635. DOI: 10.1371/journal.pone.0004824. View

10.

Corya S, Williamson D, Sanger T, Briggs S, Case M, Tollefson G . A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety. 2006; 23(6):364-72. DOI: 10.1002/da.20130. View

11.

Thase M, Corya S, Osuntokun O, Case M, Henley D, Sanger T . A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry. 2007; 68(2):224-36. DOI: 10.4088/jcp.v68n0207. View

12.

Reeves H, Batra S, May R, Zhang R, Dahl D, Li X . Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2008; 69(8):1228-1236. DOI: 10.4088/jcp.v69n0805. View

13.

Guo W, Liu F, Xue Z, Gao K, Wu R, Ma C . Altered white matter integrity in young adults with first-episode, treatment-naive, and treatment-responsive depression. Neurosci Lett. 2012; 522(2):139-44. DOI: 10.1016/j.neulet.2012.06.027. View

14.

El-Khalili N, Joyce M, Atkinson S, Buynak R, Datto C, Lindgren P . Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled.... Int J Neuropsychopharmacol. 2010; 13(7):917-32. DOI: 10.1017/S1461145710000015. View

15.

Cipriani A, Furukawa T, Salanti G, Geddes J, Higgins J, Churchill R . Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009; 373(9665):746-58. DOI: 10.1016/S0140-6736(09)60046-5. View

16.

Frank E, Prien R, Jarrett R, Keller M, Kupfer D, Lavori P . Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991; 48(9):851-5. DOI: 10.1001/archpsyc.1991.01810330075011. View

17.

Bauer M, Pretorius H, Constant E, Earley W, Szamosi J, Brecher M . Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009; 70(4):540-9. DOI: 10.4088/jcp.08m04629. View

18.

Berman R, Fava M, Thase M, Trivedi M, Swanink R, McQuade R . Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009; 14(4):197-206. DOI: 10.1017/s1092852900020216. View

19.

Deshauer D, Moher D, Fergusson D, Moher E, Sampson M, Grimshaw J . Selective serotonin reuptake inhibitors for unipolar depression: a systematic review of classic long-term randomized controlled trials. CMAJ. 2008; 178(10):1293-301. PMC: 2335186. DOI: 10.1503/cmaj.071068. View

20.

Berman R, Marcus R, Swanink R, McQuade R, Carson W, Corey-Lisle P . The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007; 68(6):843-53. DOI: 10.4088/jcp.v68n0604. View